Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Jazz Pharmaceuticals plc

NASDAQ: JAZZ · Life Sciences · 12 alerts · CIK 1232524

Share price
$239.77Close, Nov 16
Market cap
$15.4B
Shares outstanding
64.19MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Jazz Pharmaceuticals plc filings on SEC EDGAR ↗

4:46 PM ET Form 4
Insider Selling

Jazz Pharmaceuticals Insider Bruce C. Cozadd Sells $16.2M of Stock

Bruce C. Cozadd sold 68,808 shares of Jazz Pharmaceuticals plc at $234.91 to $237.39 a share (average $235.95) in 4 transactions, worth $16.2M in total on Nov 6, 2026. Shares held after the trade: 357,567 (-1.6%).

Value
$16.2M
Shares
68,808
Average price
$235.95
Holding change
-1.6%
Trade date
Nov 6, 2026
5:20 PM ET Form 4
Insider Selling

Jazz Pharmaceuticals SVP, CAO Patricia Carr Sells $327K of Stock

Patricia Carr, SVP, CAO, sold 1,413 shares of Jazz Pharmaceuticals plc at $231.27 to $231.37 a share (average $231.36) in 2 transactions, worth $327K in total on Nov 4, 2026. Shares held after the trade: 6,512 (-2.4%).

Value
$327K
Shares
1,413
Average price
$231.36
Role
SVP, CAO
Holding change
-2.4%
Trade date
Nov 4, 2026
6:29 PM ET Form 4
Insider Selling

Jazz Pharmaceuticals President & CEO Renee D. Gala Sells $225K of Stock

Renee D. Gala, President & CEO, sold 1,000 shares of Jazz Pharmaceuticals plc at $225.37 a share, worth $225K in total on Nov 3, 2026. Shares held after the trade: 140,394 (-0.7%).

Value
$225K
Shares
1,000
Price
$225.37
Role
President & CEO
Holding change
-0.7%
Trade date
Nov 3, 2026
6:35 PM ET Form 4
Insider Selling

Jazz Pharmaceuticals Insider Bruce C. Cozadd Sells $1.3M of Stock

Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals plc at $215.84 a share, worth $1.3M in total on Nov 2, 2026. Shares held after the trade: 339,875 (-1.7%).

Value
$1.3M
Shares
6,000
Price
$215.84
Holding change
-1.7%
Trade date
Nov 2, 2026
4:08 PM ET 8-K
Financial Results

Jazz Pharmaceuticals Financial Results

Jazz Pharmaceuticals reported record third-quarter 2026 revenues of $1.2 billion, a 10% increase year-over-year, driven by strong performance from Xywav and the launch of Ziihera. The company raised its full-year 2026 revenue guidance to a range of $4.775 billion to $4.85 billion and highlighted the closing of its acquisition of Actio Biosciences.

“Our third-quarter performance reflects sustained execution across the business and gives us confidence to raise our full-year total revenue guidance. At the same time, we continue to strengthen the drivers of our future growth, with the approval and rapid launch of Ziihera in first-line HER2-positive GEA and the acquisition of Actio, which adds ABS-1230 and deepens our pipeline in rare, refractory epilepsies. Jazz is moving with momentum and urgency to advance practice-changing medicines that deliver meaningful benefit for patients and durable value for shareholders.”

Renee Gala, president and chief executive officer of Jazz Pharmaceuticals
4:03 PM ET 8-K
Business Update

Jazz Pharmaceuticals Business Update

Jazz Pharmaceuticals provided a preliminary update on its Q3 2026 financial results, estimating a $755 million pre-tax charge for acquired in-process research and development (IPR&D) related to its acquisition of Actio Biosciences. This non-deductible charge is expected to have an unfavorable impact of approximately $11.00 on both GAAP and non-GAAP adjusted earnings per share for the quarter.

Counterparty
Actio Biosciences, Inc.
9:02 AM ET 8-K
Leadership Change

Jazz Pharmaceuticals Leadership Change

Samantha Pearce, Executive Vice President and Chief Commercial Officer of Jazz Pharmaceuticals, notified the company of her intent to retire. Her departure will be effective upon the appointment of a successor or by June 30, 2027, and the company has initiated a formal search process for her replacement.

5:44 PM ET Form 4
Insider Selling

Jazz Pharmaceuticals President & CEO Renee D. Gala Sells $473K of Stock

Renee D. Gala, President & CEO, sold 2,000 shares of Jazz Pharmaceuticals plc at $236.40 a share, worth $473K in total on Oct 6, 2026. Shares held after the trade: 141,394 (-1.4%).

Value
$473K
Shares
2,000
Price
$236.40
Role
President & CEO
Holding change
-1.4%
Trade date
Oct 6, 2026
4:19 PM ET Form 4
Insider Selling

Jazz Pharmaceuticals Insider Bruce C. Cozadd Sells $1.38M of Stock

Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals plc at $230.33 a share, worth $1.38M in total on Oct 1, 2026. Shares held after the trade: 345,875 (-1.7%).

Value
$1.38M
Shares
6,000
Price
$230.33
Holding change
-1.7%
Trade date
Oct 1, 2026
4:16 PM ET 8-K
Loan & Debt

Jazz Pharmaceuticals $1.9B Debt Financing with Bank of America, N.A.

Jazz Pharmaceuticals' subsidiary, Jazz Financing Lux S.à r.l., entered into a repricing amendment to its credit agreement to refinance $1.895 billion in outstanding term loans. The new Tranche B-3 Dollar Term Loans extend the maturity date from May 2028 to May 2033 and reduce the interest rate margin by 50 basis points to Term SOFR plus 1.75%.

Value
$1.9B
Counterparty
Bank of America, N.A.
Term
through May 2033

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.